Cancer immunotherapies
Scancell develops treatments that train the immune system to attack cancer, including vaccine and T-cell based drug candidates in its pipeline.
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Scancell Holdings is a UK biotechnology company focused on making new cancer treatments, especially immunotherapies that help the body’s immune system find and attack tumors. Its main work is developing drug candidates in the lab and through clinical trials rather than selling finished medicines today. The company is built around a small number of proprietary platforms, including programs aimed at cancer and some infectious disease targets.
Scancell’s customers are not patients in the usual retail sense. Its main business relationships are with hospitals and trial sites that run studies, research partners, and larger pharmaceutical companies that may license or collaborate on its science. It makes money mainly through research funding, collaboration income, and any future licensing or commercialization deals if its drug candidates are approved and adopted.
What makes Scancell different is that it sits very early in the drug value chain: it is a research-driven developer that creates immune-based therapies and then tries to prove they work well enough to partner with a bigger drug maker or bring them to market. That means the company’s value depends on turning scientific ideas into medicines, not on manufacturing and selling large volumes of products itself.
We rebuilt our DCF valuation models from the ground up and upgraded how Intrinsic Value is calculated. Alpha Spread now selects the method that best fits each company.
You can now see how the new methodology performed across thousands of stocks on our new Valuation Backtest page. We update the results at the end of every month.
New to Alpha Spread? Create free account
By using Alpha Spread you are agreeing to our Terms of Service and Privacy Policy.
Already have an account? Sign in
Stock intrinsic value is the real worth of a company's stock, based on its financial health and performance.
Instead of looking at the stock's current market price, which can change due to people's opinions and emotions, intrinsic value helps us understand if a stock is truly a good deal or not.
By focusing on the company's actual financial strength, like its earnings and debts, we can make better decisions about which stocks to buy and when.
Read more